Noam E Kopmar, Kim Quach, Ted A Gooley, Christen H Martino, Sindhu Cherian, Mary-Elizabeth M Percival, Anna B Halpern, Cristina M Ghiuzeli, Vivian G Oehler, Janis L Abkowitz, Roland B Walter, Ryan D Cassaday
IMPORTANCE: Options for adults with relapsed or refractory B-cell acute lymphoblastic leukemia or lymphoma (B-ALL) are limited, and new approaches are needed. Inotuzumab ozogamicin (InO) has been combined with low-intensity chemotherapy, with modest improvements over historical controls, and dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) treatment is safe and active for newly diagnosed ALL. OBJECTIVE: To assess the safety and clinical activity of DA-EPOCH and InO in adults with relapsed or refractory B-ALL...
May 9, 2024: JAMA Oncology